Table 4.
Three-year conditional survival upon survival (%) for 2 years and 95% confidence intervals for all primary brain tumors by histology and age group
| Category | Age at diagnosis, years | |||
|---|---|---|---|---|
| >20 | 20–44 | 45–64 | 65+ | |
| All brain tumors | 93.5 (92.2–94.5) | 86.2 (84.9–87.3) | 87.8 (86.5–89.0) | 85.9 (83.7–87.9) |
| Tumor behavior | ||||
| Malignant | 90.7 (88.8–92.3) | 75.3 (73.2–77.2) | 66.2 (63.1–69.0) | 58.4 (52.9–63.4) |
| Nonmalignant | 97.9 (96.3–98.8) | 98.7 (97.9–99.2) | 98.5 (97.3–99.2) | 92.9 (90.3–94.8) |
| Specified histologic subtypes | ||||
| Primarily malignant | ||||
| Diffuse astrocytoma | 97.5 (83.0–99.6) | 69.8 (59.0–78.4) | 62.9 (39.5–79.4) | 9.3 (0.5–34.0) |
| Anaplastic astrocytoma | 78.7 (60.4–89.3) | 64.2 (57.2–70.4) | 50.3 (38.4–61.1) | 28.5 (8.6–52.6) |
| Glioblastoma | 70.0 (45.1–85.3) | 46.2 (38.4–53.7) | 28.0 (21.8–34.5) | 24.5 (14.0–36.5) |
| Oligodendroglioma | 98.6 (88.9–99.8) | 88.7 (84.6–91.8) | 80.3 (72.6–86.0) | 81.2 (57.1–92.5) |
| Anaplastic oligodendroglioma | –a | 71.9 (56.8–82.5) | 68.1 (50.7–80.5) | 80.7 (19.1–97.3) |
| Mixed glioma | 95.9 (73.5–99.4) | 74.3 (64.0–82.0) | 69.7 (52.9–81.5) | 74.5 (27.8–93.5) |
| Astrocytoma (NOS) | 96.0 (92.6–97.9) | 72.6 (67.9–76.7) | 68.2 (59.8–75.3) | 45.3 (27.4–61.5) |
| Glioma malignant (NOS) | 93.3 (87.0–96.6) | 79.6 (70.1–86.4) | 71.8 (57.4–82.0) | 57.1 (25.4–79.5) |
| Embryonal/primitive medulloblastoma | 88.8 (84.2–92.2) | 76.2 (65.7–83.9) | 76.7 (40.3–92.6) | –a |
| Lymphoma | –a | 66.9 (51.4–78.5) | 66.8 (55.1–76.1) | 50.1 (38.4–60.8) |
| Meningioma, malignant | –a | 85.3 (60.3–95.1) | 89.2 (75.7–95.4) | 75.8 (59.5–86.2) |
| Neoplasm, unspecified | 93.6 (76.6–98.4) | 88.7 (74.6–95.3) | 92.2 (75.4–97.7) | 70.2 (52.2–82.5) |
| Ependymoma | 85.7 (78.2–90.8) | 95.8 (90.7–98.2) | 95.2 (85.1–98.5) | 85.4 (55.8–95.8) |
| Germ cell tumor | 95.6 (88.2–98.4) | 97.4 (79.4–99.7) | –a | –a |
| Primarily nonmalignant | ||||
| Pilocytic astrocytoma | 97.2 (94.9–98.5) | 95.7 (89.1–98.3) | 93.1 (65.8–98.8) | –a |
| Hemangioblastoma/hemangioma | –a | 100b | 91.2 (78.1–96.6) | 89.1 (46.9–98.3) |
| Craniopharyngioma | 100b | 97.0 (79.4–99.6) | 89.3 (56.7–97.8) | 81.7 (35.2–96.2) |
| Meningioma, nonmalignant | 100b | 98.9 (97.1–99.5) | 98.5 (96.7–99.3) | 93.6 (90.4–95.7) |
| Nerve sheath and other cranial/spinal nerve tumor | 91.7 (53.6–98.8) | 98.7 (94.9–99.7) | 99.4 (96.0–99.9) | 98.8 (92.5–99.8) |
| Pituitary tumor | 100b | 98.7 (96.8–99.5) | 97.7 (93.7–99.1) | 89.2 (82.0–93.7) |
| Neuronal/glial, nonmalignant and malignant | 92.6 (82.8–96.9) | 93.0 (81.2–97.5) | 88.0 (67.5–96.0) | –a |
| All other brain tumors | 93.5 (92.2–94.5) | 86.2 (84.9–87.3) | 87.8 (86.5–89.0) | 85.9 (83.7–87.9) |
a The overall sample size was less than 16 cases.
b Confidence interval undefined.
NOS = Not otherwise specified.